Lisata Therapeutics Inc (LTS:0HS8)
$ 3.0243 0 (0%) Market Cap: 24.21 Mil Enterprise Value: -13.88 Mil PE Ratio: 0 PB Ratio: 0.63 GF Score: 42/100

Q3 2020 Caladrius Biosciences Inc Earnings Call Transcript

Nov 05, 2020 / 09:30PM GMT
Release Date Price: $35.1
Operator

Welcome to the Caladrius Biosciences Third Quarter 2020 Financial Results and Business Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, Thursday, November 5, 2020.

I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead, sir.

John D. Menditto
Caladrius Biosciences, Inc. - VP of IR & Corporate Communications

Thank you, operator, and good afternoon, everyone. Welcome to Caladrius' third quarter 2020 conference call to discuss our financial results. Joining me today is Dr. David Mazzo, the company's President and Chief Executive Officer.

Earlier today, we issued a press release announcing our third quarter financial results, which is available under the Investors section of the company website. If you have not received this news release or you'd like to be added to the company's e-mail distribution list, please e-mail me at [email protected].

Before we begin, I remind you that comments made

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot